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Abstract
Because of the high costs associated with ascertainment of families most linkage studies of
Bipolar I disorder (BPI) have used relatively small samples. Moreover, the genetic information
content reported in most studies has been less than 0.6. While microsatellite markers spaced every
10 centimorgans typically extract most of the genetic information content for larger multiplex
families, they can be less informative for smaller pedigrees especially for affected sib pair
kindreds. For these reasons we collaborated to pool family resources and carry out higher density
genotyping. Approximately 1100 pedigrees of European ancestry were initially selected for study
and were genotyped by the Center for Inherited Disease Research using the Illumina Linkage
Panel 12 set of 6090 SNPs. Of the ~1100 families, 972 were informative for further analyses and
mean information content was 0.86 after pruning for LD. The 972 kindreds include 2284 cases of
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BPI disorder, 498 individuals with Bipolar II disorder (BPII) and 702 subjects with Recurrent
Major Depression. Three affection status models were considered: ASM1 (BPI and
schizoaffective disorder, BP cases (SABP) only), ASM2 (ASM1 cases plus BPII) and ASM3
(ASM2 cases plus Recurrent Major Depression). Both parametric and non-parametric linkage
methods were carried out. The strongest findings occurred at 6q21 (Nonparametric Pairs Lod 3.4
for rs1046943 at 119 cM) and 9q21 (Nonparametric Pairs Lod 3.4 for rs722642 at 78 cM) using
only BPI and SA, BP cases. Both results met genome-wide significant criteria, although neither
was significant after correction for multiple analyses. We also inspected parametric scores for the
larger multiplex families to identify possible rare susceptibility loci. In this analysis we observed
59 parametric lods of 2 or greater, many of which are likely to be close to maximum possible
scores. While some linkage findings may be false positives the results could help prioritize the
search for rare variants using whole exome or genome sequencing.
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Introduction
Bipolar I disorder (BPI), also termed Manic-Depressive Illness (MDI), is a complex
neuropsychiatric disorder afflicting approximately 1% of the worldwide population (APA
2000). Onset of illness typically occurs in late adolescence to early adulthood when
individuals present with acute mania, severe depression or mixed mood states. For most
persons the disorder is lifelong with recurring episodes of mania and/or depression. BPI
causes substantial morbidity with high costs to the individuals as well as society, and an
estimated 10% of those afflicted die by suicide. As mania and depression are seemingly
antipodal neurobiological states BPI disorder is one of the most enigmatic of medical
illnesses.
Although fundamental neurobiological alterations underlying illness are not yet known,
family, twin and adoption studies indicate that BPI is genetically-based with heritability
estimates of 80%.1 These studies also show that BPI displays variable expressivity, reduced
penetrance and unknown modes of inheritances. Results of some segregation analyses
implicate major loci in a subset of pedigrees.2, 3 As the disorder is relatively common BPI is
likely to have substantial genetic heterogeneity, both allelic and non-allelic (locus). Similar
to other complex genetic disorders such as diabetes, autoimmune disorders, cardiovascular
disease and Alzheimer Disease, the genetic architecture is likely to be comprised of both
common and rare variants.
For most of the past few decades linkage analysis has been the only genome-wide method
available for mapping genetic illnesses. It is robust to allelic heterogeneity (although not to
locus heterogeneity) and is optimal for mapping rare variants with relatively large effect
sizes. Over 25 genome-wide linkage studies of BPI have been completed using mostly
small/nuclear pedigrees derived from outbred populations and results are compatible with
the presence of large effect size rare alleles with substantial locus heterogeneity.4 Meta-
analyses have produced some significant findings although these results were based on
molecular methods with lower information content than methods currently available.5
Genome-wide linkage analyses of uniquely large pedigrees - mostly from isolated
populations - have also implicated a number of chromosomal regions, 6, 7, 8, 9, 10, 11 many
generating lods of 3 or more in individual pedigrees. Firm replication has not been achieved
for any of these implicated regions but this is not surprising since exceedingly large samples
are required for replication.12
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Association analysis is more robust than linkage given a wider range of locus heterogeneity
(though not allelic heterogeneity) and is a powerful method for mapping common alleles
with small effect sizes. By the mid 2000s the completion of the second-generation haplotype
map of the human genome (HapMap2) coupled with the advent of low-cost genotyping
platforms for interrogation of several hundred thousand single nucleotide polymorphisms
(SNPs), made genome-wide association studies GWAS feasible. GWAS has been
tremendously successful for mapping common variants for over 40 complex
disorders.13, 14, 15 While GWAS findings represent a significant biomedical advance, the
implicated loci explain no more than 5 to 10% of the genetic liability for any disorder. Most
associated SNPs give no insight into disease mechanisms. Initial GWAS for BPI using
modest sample sizes (~a few thousand cases and controls) produced some suggestive results.
Subsequent meta-analyses (comprised of several thousand cases and controls) yielded
significant evidence for association to a few loci including CACNA1C and
ANK3.16, 17, 18, 19, 20, 21, 22 These results represent a significant advance in unraveling the
genetics of bipolar disorder, however, the identified loci to date explain only 1 to 2% of
disease liability.
In contrast to GWAS, sample sizes for linkage studies have been comparatively small, due
in part to the high costs and effort necessary for the ascertainment of multiplex pedigrees
(versus individual cases and controls). As a result, almost all linkage studies have been
significantly underpowered. In addition, the genetic information content for the vast
majority of linkage studies has been under 60%. For these reasons we established a
collaboration to pool family resources to carry out higher density genotyping. We report
genome-wide linkage analyses for 972 pedigrees genotyped with the Illumina 6K SNP array.
The families reported here include 2284 individuals with BPI disorder (140 are
schizoaffective, bipolar type -(SABP)), 498 with BPII disorder and 702 with Recurrent
Major Depression.
Materials and Methods
Subjects
The sample is described in Supplementary Table 1. For this study, only European-American
samples were genotyped. Three different affection status models (ASMs) are used: ASM1:
Bipolar I and SABP; ASM2: ASM1 and bipolar II; and ASM3: ASM2 and recurrent major
depression. For each model, only individuals without significant mood, anxiety, or psychotic
disorders were coded as unaffected. The remaining individuals were coded as unknown.
Supplementary Table 2 lists the number of relative pairs that are concordantly affected or
unaffected, or discordant for each of the 3 ASMs. Supplementary Table 3 shows the
distribution of the number of affected individuals per pedigree.
All subjects underwent semi-structured interviews and hospital records were obtained where
available. All information for each subject was evaluated by two experienced clinicians
whom made consensus diagnoses. When the two clinicians disagreed, a third clinician
derived the final diagnoses. Individuals from the NIMH Genetics Initiative were interviewed
using the Diagnostic Interview for Genetic Studies (DIGS.23 DSM-IIIR criteria were used
for BPI diagnoses and Research Diagnostic Criteria (RDC) were used for BPII and
Recurrent Major Depression Diagnoses.24 Subjects ascertained at Cardiff University and
Trinity College Dublin were interviewed using the Schedule for Clinical Assessment in
Neuropsychiatry25 and DSM-IV criteria were applied for all diagnoses. Individuals
identified by Johns Hopkins University (JHU) were assessed either using the Lifetime
Version of the Schedule for Affective Disorders and Schizophrenia (SADS-L) or the
DIGS.26 Research Diagnostic Criteria were used for all JHU diagnoses. Individuals
evaluated by the University of California San Diego (UCSD) were interviewed using the
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Structured Clinical Interview for DSM-IIR (SCID) except those derived from the first
family ascertained for which the SADS-L was used.27 The UCSD Diagnoses were made
using DSM-IIIR criteria, modified to require a 2-day minimum duration for hypomania.
Individuals at Edinburgh were assessed using the SADS-L and DSMIIR criteria were
used.28 NIMH-Intramural/University of Chicago families were assessed using SADS-L.29
Families from the UCSF/Utah site were interviewed using the SADS-L and RDC were used
for all diagnoses.30
Genotyping
Genotyping was performed by the Center for Inherited Disease Research (CIDR) using the
Illumina Linkage Panel 12 set of 6090 SNPs. Five thousand six hundred seventy (5670)
autosomal and X-linked SNPs passed CIDR’s quality control (QC). The investigators
assessed the SNPs for missingness, allele frequency and Hardy-Weinberg equilibrium using
PLINK (http://pngu.mgh.harvard.edu/purcell/plink/) analysis.31 Mendelian errors were
assessed by both PLINK and Pedcheck (http://watson.hgen.pitt.edu/register/docs/
pedcheck.html) analyses,32 and if there were errors in a pedigree, the SNP was set to
missing for all members in the pedigree. Unlikely recombinants were assessed by Merlin
(http://www.sph.umich.edu/csg/abecasis/merlin/index.html) analysis 33 and problematic
genotypes were set to missing. Five thousand six hundred forty two (5642) autosomal and
X-linked SNPs were included in the linkage analysis. Missingness was less than 3% for
SNPs and less than 2% for genotyped individuals, frequency was at least 1%, and Hardy-
Weinberg Equilibrium p-value > 0.001 for these SNPs.
Pedigree relationship checks
PLINK analysis was used to identify unexpected relatedness between pedigrees, using
Identity By Descent (IBD) scores across all the SNPs and gender misspecification by
looking at homozygosity of X-linked SNPs. PREST (http://fisher.utstat.toronto.edu/sun/
Software/Prest/) analysis34 was used to test whether the observed IBD scores were
consistent with reported relationships within pedigrees. For the PREST analysis, a subset of
4969 autosomal SNPs with low linkage disequilibrium (LD) (pairwise r2 < 0.5) was used.
Eight duplicate pairs were found and any duplicate that was inconsistent with the rest of the
pedigree was excluded. In two instances, partial pedigree overlaps were identified between 2
sites (UCSD and JHU, NIMH and UCSF/Utah). These pedigrees were joined, using the
observed IBD scores to identify the relationships. If phenotype information for the
overlapping samples did not agree between sites, then the individual’s phenotype was set to
unknown (1/5 overlapping samples). In another pair of pedigrees from 2 sites, a parent in an
NIMH pedigree was consistent with being a child in an NIMH-Intramural/Chicago pedigree.
These 2 pedigrees were merged. Two UCSF/Utah pedigrees had founders that were siblings
and these pedigrees were merged. For 22 samples, genetic gender was not consistent with
reported gender. If the IBD scores were otherwise consistent with the reported relationship,
the gender was changed; otherwise, the individual was discarded. Pedigree structures were
corrected when relationships determined by IBD were unambiguous; otherwise, samples
were discarded. PLINK IBD and PREST analyses were performed after modifications to
assess the accuracy of the pedigree relationships.
Ancestry Analysis
Principal Components Analysis, as implemented in EIGENSOFT,35 was used to identify
subjects of non-European-American ancestry. The genotype data for the founders of each of
the pedigrees was combined with genotypes from the HapMap sample (founders only) for
the CEPH, Yoruban, Japanese, and Chinese sample. HapMap genotypes that did not overlap
with the linkage sample were discarded. The first 2 components of the PCA analysis were
plotted (Supplementary Figure 1). None of the samples clustered with the Yoruban or Asian
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samples and almost all of the samples clustered with the CEPH sample. Individuals from 10
families (4 NIMH, 2 JHU, 3 Cardiff, 1 UCSD) were identified as outliers and these 10
families were discarded from the analysis.
Linkage Analysis
Parametric and non-parametric analyses were performed for 3 affection status models
(ASMs) using two different methods of analysis. All SNPs were analyzed with Merlin
version 1.1.233 using the correction for LD by identifying clusters of SNPs with pairwise LD
of at least 0.1. Large pedigrees were trimmed using PedShrink software (http://
mayoresearch.mayo.edu/schaid_lab/software.cfm), which trims pedigrees to a specified bit
size and prioritizes trimming uninformative individuals. All informative individuals were
analyzed with MORGAN version 3.036(http://www.stat.washington.edu/thompson/Genepi/
pangaea.shtml) which uses Markov chain Monte Carlo methods for linkage mapping in large
pedigrees. A subset of 4679 SNPs with pairwise r2 < 0.1 was used in the MORGAN linkage
analysis.
Parametric heterogeneity (HLOD) scores under dominant model (risk allele frequency 0.01,
penetrances 0.01, 0.70, 0.70) and recessive model (risk allele frequency 0.1, penetrances
0.01, 0.01, 0.70) were calculated in Merlin and MORGAN/ lm_markers. These models are
powerful for rare, relatively highly penetrant susceptibility alleles. Nonparametric linkage
analyses were performed using 1) the SAll statistic under the exponential model 37
implemented in Merlin which can be powerful in datasets that show very strong linkage
signals or which include larger pedigrees; 2) the SPairs statistic under the linear model 37
implemented in Merlin, which may be more powerful for relatively common alleles; 3) the
Spairs statistic implemented in MORGAN/lm_ibdtests; and 4) the Slambda statistic
implemented in MORGAN/lm_ibdtests which incorporates affected and unaffected
individuals. For the MORGAN nonparametric tests, the normality-based tests, rather than
assessing significance through permutation of affection status, were used as many families
did not have unaffected relatives.
Sex-specific genetic maps were obtained from Rutgers Map Interpolator software (http://
compgen.rutgers.edu/old/map-interpolator) that estimates genetic distances from the
physical locations of the SNPs, using the Rutgers combined linkage physical map of the
human genome. 38
Thresholds for suggestive and significant linkage for each analysis were estimated from the
data using autoregressive models to estimate the correlation between standard normal
statistics at adjacent map points and then using this correlation to estimate study-specific
critical values (http://www.wpic.pitt.edu/wpiccompgen/
robust_estimation_genome_scan.htm). 39
Covariate Analyses
Information on age of onset, presence of psychosis, presence of mood-incongruent
psychosis, and suicide attempts was present for most of the families studied. The effects of
these covariates on linkage were analyzed using Ordered Subsets Analysis 40 as
implemented in FLOSS (Flexible Ordered Subset Analysis).41 Covariate designation was
pedigree-specific. For age of onset, pedigrees were classified based on the youngest age of
onset within a pedigree. For the other covariates, pedigrees were classified by the presence
of at least one individual who was positive for the covariate. Also, the number of affected
individuals within a pedigree was analyzed as a covariate as pedigrees with many affected
individuals may be segregating for different loci (possibly with rarer, more highly penetrant
alleles) than pedigrees with few affected individuals. Nonparametric linkage (NPL) scores
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for each pedigree were calculated by Merlin using the Spairs statistic. Families were ordered
by covariate scores. Families with the same covariate score had the same rank. Thus, for
binary covariates, there were only 2 subsets of families. Multipoint linkage was performed
on the subset of families with the k-smallest or k-largest scores. The permutation test
compared the maximum ordered subset linkage score for the covariate score by ordering of
the families with the maximum ordered subset linkage scores obtained for random orderings
of the families. Permutation controls for multiple testing of all regions of a single
chromosome but not for multiple chromosomes or multiple covariates.
Age of onset, presence of psychosis, presence of mood-incongruent psychosis, and suicide
attempts were also analyzed as phenotypes. For binary covariates, individuals were
considered affected if they were positive for the covariate and unknown otherwise. These
covariates were analyzed with Merlin using the SAll statistic under the exponential model
and the SPairs statistic under the linear model. Age of onset was analyzed with variance
components analysis as implemented in Merlin. This analysis partitions the variance of the
trait into the following components: major locus, a polygenic component and non-genetic
variation.
Imprinting Analyses
Imprinting was analyzed using GeneFinder42 (http://people.virginia.edu/~wc9c/genefinder/
index.html) with linkage extensions. This analysis uses generalized estimating equations to
test whether sharing of maternal alleles among affected sib pairs is significantly different
from sharing of paternal alleles. For this analysis, extended IBD scores were calculated
using Merlin.
Results
Nonparametric and parametric linkage analyses
The critical lod scores for suggestive (occurring once by chance in a single genome scan),
significant (probability of 0.05 of occurring in a single genome scan by chance), and
significant criteria with Bonferroni correction for 24 different analyses, are presented in
Supplementary Table 4. Bonferroni correction is likely to be overly conservative as the
analyses are not independent of each other. Suggestive criteria scores range from 1.9-2.3,
significant criteria scores range from 3.2-3.6, and criteria scores after correcting for multiple
testing are 4.5-5.0. Information content was estimated using Merlin’s entropy measure,
where 1 is completely informative. Mean information content was 0.87 (s.d. 0.026) for all
the SNPs and 0.86 (s.d. 0.028) for SNPs after pruning for LD.
Supplementary Figures 2, 3, and 4 show the Merlin results for ASM1, ASM2, and ASM3
respectively. Table 1 presents all results that meet suggestive criteria for significance.
Results that met significant criteria are found at 6q21 for ASM1 (Pairs Lod 3.4 for
rs1046943 at 119 cM) and 9q21 for ASM1 (Pairs Lod 3.4 for rs722642 at 78 cM).
Suggestive results were found in 10 additional regions. No results were significant after
correcting for multiple analyses.
The MORGAN linkage results are presented in Supplementary Figures 5, 6, and 7 for
ASM1, ASM2, and ASM3 respectively. Table 2 presents all the results that met the
suggestive criteria for significance. No results met the significant criteria. With the
exception of 15q22 for ASM2 (Slambda lod 3.0 for rs782944 at 60 cM), all of the regions
presented in Table 6 also met a minimum suggestive criteria for significance in the Merlin
analyses.
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Table 3 presents the results from the MORGAN parametric analyses for which the lod score
for a single pedigree exceeds 2. While most of these results are likely to be false positives,
inspection of results for larger families may suggest regions in which a rare, highly penetrant
locus exists, particularly when 3 or more families show elevated lod scores in the same
region. Such regions include chromosome 4 (152-214 cM) and chromosome 19 (23-58 cM).
The exploratory covariate analyses performed using FLOSS identified genome-wide
significant regions of enhanced linkage for families with more affected individuals, younger
ages of onset, and lack of psychosis. However, no results were significant when corrected
for the number of phenotypes tested. All genome-wide significant results are presented in
Table 4. Families with younger ages of onset demonstrated enhanced evidence of linkage for
chromosome 2 at 118 cM (ASM2 – Base NPL 3.24, Subset NPL 5.18, p=0.0007, 429/785
families). Linkage to chromosome 8 at 82 cM was enhanced in families without psychosis
(ASM3 – Base NPL 2.02, Subset NPL 3.76, p=0.0015, 173/943 families). Families with a
larger number of affected individuals showed increased evidence for linkage on
chromosome 12 at 97 cM (ASM2 – Base NPL 2.40, Subset NPL 4.36, p=0.0015, 27/872
families)
The results for the exploratory analyses using the covariates as phenotypes include: 1)
psychosis showed a Exp lod score of 2.23 on chromosome 12 at 122 cM, an Exp lod score
of 2.27 on chromosome 15 at 23 cM, a Pairs lod of 2.27 on chromosome 18 at 64 cM and a
Pairs lod of 2.1 on chromosome 18 at 83 cM and 2) mood-incongruent psychosis showed a
Pairs lod of 2.03 on chromosome 18 at 33 cM. Neither analysis met genome-wide
significance. Finally, there was no evidence of imprinting from the GENEFINDER analyses
(results not shown).
Discussion
The strongest linkage findings occurred at 6q21 (Pairs Lod 3.4 for rs1046943 at 119 cM)
and 9q21 (Pairs Lod 3.4 for rs722642 at 78 cM) using only BPI and SABP cases, diagnostic
classifications that are presumably the least heterogeneous of phenotypes. Both results met
genome-wide significant criteria but were not significant when corrected for multiple
analyses. These regions did not show enhanced evidence of linkage for any of the subgroups
defined by age, psychosis, suicide, or number of affected individuals within a pedigree. The
parametric lod scores in these regions are substantially lower than the non-parametric lod
scores, suggesting low penetrance as data from unaffected individuals appear to be
detracting from the linkage results. The 6q21 linkage region was also identified in a meta-
analysis of 11 linkage studies performed by McQueen et al.5 Because there is a large overlap
between samples included in this study and the meta-analysis, these findings are not
independent. Given the overlap between the two studies, it is noteworthy that this study
found no evidence of linkage to 8q, a region identified in the meta-analysis. However, the
meta-analysis did find suggestive evidence of linkage to 9q at 46-48 cM, which is 30 cM
proximal to our finding. Under ASM1 the next two highest results occurred at 2q (Pairs Lod
3.1 at 118) and 17q (Pairs lods 2.7 at 109 cMs). Under ASM2 or ASM3 suggestive results
were found in 10 additional regions (Table 1). No results were significant after correcting
for multiple analyses.
Association analysis has been performed for the 6q21 region and bipolar disorder by Fan et
al.43 3,047 SNPs were analyzed in a case-control sample of 1064 individuals and a family-
based sample of 256 nuclear families. A replication study of 151 SNPs in 622 cases and
1181 controls, involving SLC22A16, DDO, PREP, NT5DC1, GPR6, and the region around
rs794854, was also performed. Evidence of association with SLC22A16 in all 3 samples,
although not consistently with the same SNPs, was found. SLC22A16 encodes an organic
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cation/carnitine transporter. Organic ion transporters transport various medically and
physiologically important compounds, including pharmaceuticals, toxins, hormones,
neurotransmitters, and cellular metabolites. For 9q21, evidence of association to NTRK2, a
tyrosine kinase receptor gene which binds with brain derived neurotrophic factor, was found
in a whole genome association study of bipolar disorder African-Americans.21 However,
there was no association found in the European-American sample in this region.
Copy Number Variants (CNVs) have been analyzed by Zhang et al.44, in a sample of
individuals drawn from the NIMH families in this study. No evidence of association with a
specific CNV was found. However, singleton deletions that were present in cases but not
controls were found in 6q21 (1 case), 6q26 (2 cases, no overlap), and 9q21 (1 case). Grozeva
et al.45 analyzed CNVs in the The Wellcome Trust Case Control Consortium sample, which
includes about 50 cases that are in our linkage sample25. Significant evidence of association
between bipolar disorder and CNVs was not found in this study. CNVs present in cases but
not controls were found on 6q21 (2 cases), 6q22 (2 cases, no overlap), and 9q21 (2 cases, no
overlap).
Exploratory covariate analyses found enhanced evidence of linkage in the subset of families
with younger age of onset at 2q12, lack of psychosis at 8q13, and larger numbers of affected
individuals at 12q21. Mathieu et al.46 found evidence of linkage to 2q14, 10-30 cM away
from our finding, in the portion of their sample with age of onset less than 22 years but not
in the subsample with older age of onset. The finding on 8q13 is approximate 70 cM
proximal to the 8q linkage region reported in McQueen et al.5 and thus probably is not the
same region. Analyses using covariates as phenotypes found no genome-wide significant
findings.
We also inspected scores for the larger multiplex families and observed 59 parametric lods
of 2 or greater, many of which are close to maximum possible scores (Table 3). While some
of these lod scores may represent false positive linkage findings, there were multiple regions
in which at least 1 pedigree had a lod score of at least two. In particular chromosome 4q
(152-214 cM) and chromosome 19 (23-58 cM) are regions in which 3 or more pedigrees
showed elevated lod scores and may represent regions in which a rare, relatively penetrant
locus may be segregating in a small proportion of families. The 12q21 area may also
represent such a region as there was increased evidence for linkage in families with a larger
number of affected individuals. These data could be an invaluable asset for mapping rare
variants via genome-wide sequencing. Large families, producing relatively high lod scores,
are more likely to contain rare alleles with relatively large effect sizes. Focusing on regions
showing elevated lod scores will help reduce the number of rare variants to be examined. In
addition, co-segregation of the rare variant may be tested within large families, which will
further filter the number of variants for follow-up.
Despite a large sample of 972 pedigrees of European ancestry and almost optimal extraction
of genetic information (0.87) there were no linkage findings that met genome-wide
significance after correction of multiple testing. However, the genetic models are
interdependent and statistical correction may be overly conservative under these
circumstances. Thus, some of the linkage findings may represent true positives. A number of
factors could explain the inability to obtain robust and replicable findings in this linkage
study as well as in the field. First, the assumption that rare large-effect size alleles underlie
some of the genetic variation of bipolar disorder may be incorrect. In contrast to linkage
GWAS has found evidence for a few common loci that appear to be quite significant.
However, these loci explain only a small percent of the genetic variation. Given that both
rare and common loci have been found for most complex genetic diseases it is likely that
both rare and common variation predispose to BPI. Second, assuming rare variants exist, it
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appears that there is a large range of locus heterogeneity and that even large samples may
not have sufficient power. Linkage results reported over the last two decades are compatible
with this. Under a model of extensive locus heterogeneity uniquely large pedigrees will be
invaluable for mapping loci as the ability to ascertain thousands of smaller nuclear/sib pair
families are cost prohibitive. For this study, seven separate sites contributed families and it
is possible – if not probable – that varying fractions of families linked to particular loci are
found in each of the samples. There were also different ascertainment and diagnostic criteria
among some of the sites and this may have increased heterogeneity. Another factor that
hinders the ability to obtain replicable linkage results is that very large sample sizes are
required for replication.12 Several thousands of pedigrees may be required and it is unlikely
that this will ever be possible. While the era of large-scale linkage studies is probably over,
linkage analysis of uniquely large pedigrees may still be worthwhile.
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